Mitoconix

Mitoconix is a biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases. Its lead drug, MTC-1203, aimed at treating Huntington's disease, is in the preclinical and clinical stages of development. The company will also further expand its pipeline of drugs targeting other neurodegenerative diseases by improving mitochondrial function.